Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Oxford Cannabinoid Technologies Holdings PLC announced on Thursday that its subsidiary, OCT Victoria Pty Ltd, has entered an agreement with iNGENu CRO Pty Lt to conduct a study evaluating the safety of OCT130401.
Oxford Cannabinoid Holdings is a London-based clinical stage biopharmaceutical company focused on the development and commercialisation of cannabinoid medicines.
Its new partner, iNGENu, is an Australian-based contract research organisation that works in the cannabinoid pharmaceutical drug development and clinical research industry.
The study is a phase one randomised, double-blind, placebo-controlled dose escalation study, intended to evaluate the safety, tolerability and pharmacokinetics of OCT130401, a medical device for the treatment of chronic and severe pain conditions.
The study hopes to use OCT130401 to target trigeminal neuralgia, a chronic pain condition. Trigeminal neuralgia causes stabbing, electric shock-like facial pain, with its fast and sudden onsets making it difficult to treat. Some people with the condition suffer up to 100 episodes in a day.
Clinical trials are expected to commence in the second quarter of 2024, the company said.
Oxford Cannabinoid’s Chief Executive Officer Clarissa Sowemimo-Coker said: ‘iNGENu is a well-recognised contract research organisation, with a specific expertise in cannabinoids and the Australian regime also affords a direct path to US Food and Drug Administration approval which is an important target for the company.’
iNGENu’s Chief Executive Officer Sud Agarwal said: ‘We are delighted to be Oxford Cannabinoid Technologies’ contract research organisation partner in its first Australia-based clinical trial. Whilst many people are aware of the financial benefits of the Australian research regime, many are less aware of the world-class clinical research units and the favourable regulatory laws, allowing rapid study start-up. We look forward to kicking off this work, which is aiming to meet a significant unmet need for people living with trigeminal neuralgia.’
Oxford Cannabinoid Technologies shares rose 5.7% to 0.36 pence each in London on Thursday afternoon.
Copyright 2024 Alliance News Ltd. All Rights Reserved.